473 related articles for article (PubMed ID: 26544943)
1. Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.
Chung AW; Kumar MP; Arnold KB; Yu WH; Schoen MK; Dunphy LJ; Suscovich TJ; Frahm N; Linde C; Mahan AE; Hoffner M; Streeck H; Ackerman ME; McElrath MJ; Schuitemaker H; Pau MG; Baden LR; Kim JH; Michael NL; Barouch DH; Lauffenburger DA; Alter G
Cell; 2015 Nov; 163(4):988-98. PubMed ID: 26544943
[TBL] [Abstract][Full Text] [Related]
2. Systems serology: profiling vaccine induced humoral immunity against HIV.
Chung AW; Alter G
Retrovirology; 2017 Dec; 14(1):57. PubMed ID: 29268769
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.
Brown EP; Dowell KG; Boesch AW; Normandin E; Mahan AE; Chu T; Barouch DH; Bailey-Kellogg C; Alter G; Ackerman ME
J Immunol Methods; 2017 Apr; 443():33-44. PubMed ID: 28163018
[TBL] [Abstract][Full Text] [Related]
4. Systems serology for evaluation of HIV vaccine trials.
Ackerman ME; Barouch DH; Alter G
Immunol Rev; 2017 Jan; 275(1):262-270. PubMed ID: 28133810
[TBL] [Abstract][Full Text] [Related]
5. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
Chung AW; Ghebremichael M; Robinson H; Brown E; Choi I; Lane S; Dugast AS; Schoen MK; Rolland M; Suscovich TJ; Mahan AE; Liao L; Streeck H; Andrews C; Rerks-Ngarm S; Nitayaphan S; de Souza MS; Kaewkungwal J; Pitisuttithum P; Francis D; Michael NL; Kim JH; Bailey-Kellogg C; Ackerman ME; Alter G
Sci Transl Med; 2014 Mar; 6(228):228ra38. PubMed ID: 24648341
[TBL] [Abstract][Full Text] [Related]
6. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
7. Humoral Fingerprinting of Immune Responses: 'Super-Resolution', High-Dimensional Serology.
Lau WW; Tsang JS
Trends Immunol; 2016 Mar; 37(3):167-169. PubMed ID: 26830541
[TBL] [Abstract][Full Text] [Related]
8. Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.
Wines BD; Billings H; Mclean MR; Kent SJ; Hogarth PM
Curr HIV Res; 2017; 15(3):202-215. PubMed ID: 28322167
[TBL] [Abstract][Full Text] [Related]
9. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
Tomaras GD; Plotkin SA
Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
[TBL] [Abstract][Full Text] [Related]
10. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
Kim JH; Excler JL; Michael NL
Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
[TBL] [Abstract][Full Text] [Related]
11. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
12. IgM, not IgG, a key for HIV vaccine.
Yang QE
Vaccine; 2009 Feb; 27(9):1287-8. PubMed ID: 19146899
[TBL] [Abstract][Full Text] [Related]
13. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.
Fouts TR; Bagley K; Prado IJ; Bobb KL; Schwartz JA; Xu R; Zagursky RJ; Egan MA; Eldridge JH; LaBranche CC; Montefiori DC; Le Buanec H; Zagury D; Pal R; Pavlakis GN; Felber BK; Franchini G; Gordon S; Vaccari M; Lewis GK; DeVico AL; Gallo RC
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E992-9. PubMed ID: 25681373
[TBL] [Abstract][Full Text] [Related]
14. Prospects for a Globally Effective HIV-1 Vaccine.
Excler JL; Robb ML; Kim JH
Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
[TBL] [Abstract][Full Text] [Related]
15. Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement.
Lofano G; Gorman MJ; Yousif AS; Yu WH; Fox JM; Dugast AS; Ackerman ME; Suscovich TJ; Weiner J; Barouch D; Streeck H; Little S; Smith D; Richman D; Lauffenburger D; Walker BD; Diamond MS; Alter G
Sci Immunol; 2018 Aug; 3(26):. PubMed ID: 30120121
[TBL] [Abstract][Full Text] [Related]
16. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
[TBL] [Abstract][Full Text] [Related]
17. Moving the HIV vaccine field forward: concepts of protective immunity.
Kent SJ; Davenport MP
Lancet HIV; 2019 Jun; 6(6):e406-e410. PubMed ID: 31080107
[TBL] [Abstract][Full Text] [Related]
18. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
Haynes BF; Montefiori DC
Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638
[TBL] [Abstract][Full Text] [Related]
19. HIV/AIDS: allied responses.
Mascola JR
Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
[No Abstract] [Full Text] [Related]
20. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
